Instil Bio's Lung Cancer Drug 23% Response Rate in Phase 2, Major Results Expected Late 2025

Instil Bio (NASDAQ: TIL) and ImmuneOnco provided updates on their PD-L1xVEGF bispecific antibody IMM2510/AXN-2510 ('2510) clinical trials. The Phase 2 trial of '2510 combined with chemotherapy for first-line NSCLC in China is expected to complete enrollment of ~60 patients in Q3 2025, with initial results anticipated in 2H 2025. In relapsed/refractory NSCLC, '2510 monotherapy showed a 23% objective response rate (n=13). Instil Bio plans to initiate a Phase 1b/2 monotherapy dose optimization trial in the US by end of 2025, replacing the previously planned first-line NSCLC combination trial. A Phase 3 trial in China for first-line NSCLC is anticipated to start in mid-2026, subject to regulatory discussions.

https://www.stocktitan.net/news/TIL/instil-bio-and-immune-onco-announced-the-phase-2-trial-in-first-line-huoeb5ifzex5.html